Skip to main content
PMC home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 2000;8(5-6):240–243. doi: 10.1155/S1064744900000351

Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis.

G Sood 1, P Nyirjesy 1, M V Weitz 1, A Chatwani 1
PMCID: PMC1784691  PMID: 11220485

Abstract

OBJECTIVE: Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida albicans species, terconazole cream has not been been studied in patients with these infections. We sought to assess the clinical and mycological efficacy of terconazole cream in women with non-C. albicans vaginitis. METHODS: The records of patients who had received a 7-day course of terconazole cream for culture-proved non-C. albicans vaginitis were reviewed. Data with regard to patient demographics, clinical and mycologic response to therapy within 1 month of treatment, and outcome with other antifungal therapies were analyzed. RESULTS: Twenty-eight patients received terconazole cream for non-C. albicans infections. Three patients did not return for follow-up. The median age was 45 years. Seven (28%) patients were nulliparous. The median duration of symptoms was 3 years. Nine patients (36%) had received terconazole within the 6 months prior to referral. Overall, there were 20 C. glabrata cases, 3 C. parapsilosis, and 2 C. lusitaniae. Fourteen (56%) patients achieved a mycologic cure; 11 (44%) noted a resolution of their symptoms. Prior terconazole use was not associated with treatment failure (P = 0.09). Ten failures received boric acid suppositories as subsequent treatment; a cure was effected in 4 (40%). Two of three patients (67%) were eventually cured with flucytosine cream. Five (20 %) patients remained uncured. CONCLUSIONS: Terconazole cream may be an appropriate first-line treatment for non C. albicans vaginitis, even in patients who have previously received the drug.

Full Text

The Full Text of this article is available as a PDF (637.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agatensi L., Franchi F., Mondello F., Bevilacqua R. L., Ceddia T., De Bernardis F., Cassone A. Vaginopathic and proteolytic Candida species in outpatients attending a gynaecology clinic. J Clin Pathol. 1991 Oct;44(10):826–830. doi: 10.1136/jcp.44.10.826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cauwenbergh G., Vanden Bossche H. Terconazole. Pharmacology of a new antimycotic agent. J Reprod Med. 1989 Aug;34(8 Suppl):588–592. [PubMed] [Google Scholar]
  3. Galgiani J. N., Reiser J., Brass C., Espinel-Ingroff A., Gordon M. A., Kerkering T. M. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother. 1987 Sep;31(9):1343–1347. doi: 10.1128/aac.31.9.1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Horowitz B. J., Edelstein S. W., Lippman L. Candida tropicalis vulvovaginitis. Obstet Gynecol. 1985 Aug;66(2):229–232. [PubMed] [Google Scholar]
  5. Horowitz B. J. Mycotic vulvovaginitis: a broad overview. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1188–1192. doi: 10.1016/s0002-9378(12)90725-5. [DOI] [PubMed] [Google Scholar]
  6. Horowitz B. J. Topical flucytosine therapy for chronic recurrent Candida tropicalis infections. J Reprod Med. 1986 Sep;31(9):821–824. [PubMed] [Google Scholar]
  7. Lynch M. E., Sobel J. D. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol. 1994;32(4):267–274. [PubMed] [Google Scholar]
  8. Nyirjesy P., Seeney S. M., Grody M. H., Jordan C. A., Buckley H. R. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):820–823. doi: 10.1016/0002-9378(95)90347-x. [DOI] [PubMed] [Google Scholar]
  9. O'Connor M. I., Sobel J. D. Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of Candida albicans. J Infect Dis. 1986 Aug;154(2):358–363. doi: 10.1093/infdis/154.2.358. [DOI] [PubMed] [Google Scholar]
  10. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  11. Rex J. H., Rinaldi M. G., Pfaller M. A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995 Jan;39(1):1–8. doi: 10.1128/aac.39.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sobel J. D., Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis. 1997 Apr;24(4):649–652. doi: 10.1093/clind/24.4.649. [DOI] [PubMed] [Google Scholar]
  13. Thomason J. L. Clinical evaluation of terconazole. United states experience. J Reprod Med. 1989 Aug;34(8 Suppl):597–601. [PubMed] [Google Scholar]
  14. Vanden Bossche H., Marichal P. Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193–1199. doi: 10.1016/s0002-9378(12)90726-7. [DOI] [PubMed] [Google Scholar]
  15. White D. J., Johnson E. M., Warnock D. W. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med. 1993 Apr;69(2):112–114. doi: 10.1136/sti.69.2.112. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES